NZ Hepatitis Research Review Issue 35

In this issue:

• Serological response to HBV revaccination
• Entecavir vs tenofovir for treatment-naive chronic HBV
• HEV in patients with haematological malignancies
• Direct-acting antivirals in chronic HCV with HCC
• REAL-B risk score for prediction of HCC in chronic HBV
• Glecaprevir/pibrentasvir for chronic HCV and compensated cirrhosis
• Safety of direct-acting antiviral agents for hepatitis C
• Simplified hepatitis C virus monitoring with glecaprevir plus pibrentasvir
• Short duration glecaprevirpibrentasvir for recent HCV
• Patient-reported outcomes with direct-acting antiviral therapies for chronic HCV

Please login below to download this issue (PDF)

Subscribe